Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dynamic changes in homologous recombination status before and after chemotherapy in advanced ovarian, fallopian tube, and primary peritoneal cancers.

Journal of ovarian research - 23 Apr 2026

Morimoto Akemi, Matsumoto Takashi, Teramoto Norifumi, Murakami Sakiko, Usami Tomoka, Murai Junko, Sugiyama Takashi

Abstract excerpt

OBJECTIVE: Homologous recombination (HR) status plays a pivotal role in the management of advanced ovarian cancers, particularly in guiding the use of PARP inhibitors. In patients receiving neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS), tumor samples are available both before and after chemotherapy. This study evaluated the impact of NAC on HR status using paired pre- and post-NAC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Fallopian Tube Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomic Instability

Share to Homologous Recombination

Share to Mutation

Share to Neoadjuvant Therapy

Share to Ovarian Neoplasms

Share to Peritoneal Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 42026578
DOI: 10.1186/s13048-026-02101-1
PMCID: PMC13237896

Genes

IDS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dynamic changes in homologous recombination status before and after chemotherapy in advanced ovarian, fallopian tube, and primary peritoneal cancers.PMID 42026578Read ↗

Dynamic changes in homologous recombination status before and after chemotherapy in advanced ovarian, fallopian tube, and primary peritoneal cancersSemantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis, and TreatmentSemantic proximity Read ↗

[Analysis of homologous recombination deficiency testing in ovarian cancer based on next-generation sequencing].Semantic proximity Read ↗

Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance.Semantic proximity Read ↗

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian CancerSemantic proximity Read ↗

Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.Semantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis and TreatmentSemantic proximity Read ↗

Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian CancerSemantic proximity Read ↗

Unraveling Homologous Recombination Deficiency in Ovarian Cancer: A Review of Currently Available Testing PlatformsSemantic proximity Read ↗

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical ConsiderationsSemantic proximity Read ↗

Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.Semantic proximity Read ↗

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.